19:01 , Jun 22, 2018 |  BC Week In Review  |  Financial News

Rhythm raises $151.4M in follow-on

Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) raised $151.4 million on June 20 through the sale of 5.7 million shares at $26.42 in a follow-on underwritten by Morgan Stanley, BofA Merrill Lynch, Cowen and Needham. The price is...
14:14 , Jun 21, 2018 |  BC Extra  |  Financial News

Rhythm raises $151.4M in follow-on

Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) raised $151.4 million through the sale of 5.7 million shares at $26.42 in a follow-on underwritten by Morgan Stanley, BofA Merrill Lynch, Cowen and Needham. The price is an 8% discount...
05:06 , Mar 20, 2018 |  BC Extra  |  Preclinical News

Rhythm estimates mutations in genes tied to obesity

Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) presented an analysis of genetic epidemiology data at the Endocrine Society meeting in Chicago suggesting that about 12,800 Americans are homozygous or compound heterozygous for known and predicted loss-of-function variants in...
20:40 , Jan 5, 2018 |  BC Week In Review  |  Company News

Mallinckrodt acquiring Sucampo

Mallinckrodt plc (NYSE:MNK) said it will acquire Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) for $18 per share in a deal the companies say values Sucampo at $1.2 billion. The price is a 6% premium to Sucampo's close...
23:19 , Dec 26, 2017 |  BC Extra  |  Company News

Mallinckrodt acquiring Sucampo

Mallinckrodt plc (NYSE:MNK) said Tuesday it will acquire Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) for $18 per share in a deal the companies say values Sucampo at $1.2 billion. The price is a 6% premium to Sucampo's...
18:58 , Dec 8, 2017 |  BC Week In Review  |  Clinical News

Rhythm reports Phase II data of setmelanotide to treat Bardet-Biedl Syndrome

In October, Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) reported preliminary data from 5 Bardet-Biedl Syndrome patients with morbid obesity and hyperphagia in the Phase II portion of a Phase II/III trial showing that setmelanotide (RM-493) reduced body...
16:55 , Oct 6, 2017 |  BC Week In Review  |  Financial News

Rhythm rises on $119.9M IPO

Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) gained 76% in its first day of trading on Oct. 5 after raising $119.9 million through the sale of 7.1 million shares at $17 in a bumped-up IPO underwritten by Morgan...
20:31 , Oct 5, 2017 |  BC Extra  |  Financial News

Rhythm rises on $119.9M IPO

Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) gained $13 (76%) to $30 in its first day of trading Thursday after raising $119.9 million through the sale of 7.1 million shares at $17 in a bumped-up IPO underwritten by...
20:40 , Sep 8, 2017 |  BC Week In Review  |  Company News

Fosun gains rights to bremelanotide in China and Taiwan from Palatin

Palatin Technologies Inc. (NYSE-M:PTN) granted Shanghai Fosun Pharmaceutical Group Co. Ltd. (Shanghai:600196; HKSE:2196) exclusive rights to develop and commercialize bremelanotide in China, including Hong Kong and Macau, and Taiwan to treat hypoactive sexual desire disorder...
00:20 , May 19, 2017 |  BC Week In Review  |  Clinical News

FDA grants breakthrough therapy designation to setmelanotide for obesity

Rhythm Holding Co. LLC (Boston, Mass.) said FDA granted breakthrough therapy designation to setmelanotide (RM-493) to treat obesity associated with genetic defects upstream of the melanocortin 4 receptor (MC4R) in the leptin-melanocortin pathway, including leptin...